Published on 27 May 2023 on Benzinga via Yahoo Finance
TScan Therapeutics Inc (NASDAQ: TCRX) announced a poster presentation highlighting preliminary data from the Phase 1 umbrella clinical trial evaluating TSC-100 and TSC-101 targeting minor histocompatibility antigens to prevent relapse after hematopoietic cell transplantation in leukemia patients.
The company's Phase 1 study is rapidly enrolling, and TSC-101 is advancing into the second dose level.